139 related articles for article (PubMed ID: 32925511)
21. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.
Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Modak S; Kramer K; Roberts SS; Basu EM; Yataghene K; Cheung NK
Oncotarget; 2016 Jan; 7(4):4155-66. PubMed ID: 26623730
[TBL] [Abstract][Full Text] [Related]
22. [Clinical characteristics and prognosis of high-risk neuroblastoma with bone marrow metastasis in children].
Fan HJ; Huang C; Su Y; Wang XD; Zhou YC; Duan C; Zhao W; Zhao Q; Jin M; Ma XL
Zhonghua Er Ke Za Zhi; 2019 Nov; 57(11):863-869. PubMed ID: 31665841
[No Abstract] [Full Text] [Related]
23. [Occurrence and prognostic impact of selected factors in neuroblastoma in children].
Wieczorek A; Balwierz W
Przegl Lek; 2010; 67(6):393-8. PubMed ID: 21344768
[TBL] [Abstract][Full Text] [Related]
24. [Clinical and prognostic analysis of single-center multidisciplinary treatment for rhabdomyosarcoma in children].
Xu N; Duan C; Jin M; Zhang DW; Su Y; Yu T; He LJ; Fu LB; Zeng Q; Wang HM; Zhang WP; Ni X; Ma XL
Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):767-773. PubMed ID: 31594063
[No Abstract] [Full Text] [Related]
25. Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable
Ambros IM; Tonini GP; Pötschger U; Gross N; Mosseri V; Beiske K; Berbegall AP; Bénard J; Bown N; Caron H; Combaret V; Couturier J; Defferrari R; Delattre O; Jeison M; Kogner P; Lunec J; Marques B; Martinsson T; Mazzocco K; Noguera R; Schleiermacher G; Valent A; Van Roy N; Villamon E; Janousek D; Pribill I; Glogova E; Attiyeh EF; Hogarty MD; Monclair TF; Holmes K; Valteau-Couanet D; Castel V; Tweddle DA; Park JR; Cohn S; Ladenstein R; Beck-Popovic M; De Bernardi B; Michon J; Pearson ADJ; Ambros PF
J Clin Oncol; 2020 Nov; 38(31):3685-3697. PubMed ID: 32903140
[TBL] [Abstract][Full Text] [Related]
26. [Expression and significance of programmed cell death ligand-1 in neuroblastoma tissues].
Liao R; Sun XF; Zhen ZZ; Huang DS
Zhonghua Er Ke Za Zhi; 2018 Oct; 56(10):735-740. PubMed ID: 30293276
[No Abstract] [Full Text] [Related]
27. Outcome in neuroblastoma.
Ozguven AA; Anak S; Unuvar A; Akcay A; Karakas Z; Ozturk G; Devecioglu O; Agaoğlu L
Indian J Pediatr; 2015 May; 82(5):450-7. PubMed ID: 25274444
[TBL] [Abstract][Full Text] [Related]
28. Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study.
Holmes K; Pötschger U; Pearson ADJ; Sarnacki S; Cecchetto G; Gomez-Chacon J; Squire R; Freud E; Bysiek A; Matthyssens LE; Metzelder M; Monclair T; Stenman J; Rygl M; Rasmussen L; Joseph JM; Irtan S; Avanzini S; Godzinski J; Björnland K; Elliott M; Luksch R; Castel V; Ash S; Balwierz W; Laureys G; Ruud E; Papadakis V; Malis J; Owens C; Schroeder H; Beck-Popovic M; Trahair T; Forjaz de Lacerda A; Ambros PF; Gaze MN; McHugh K; Valteau-Couanet D; Ladenstein RL;
J Clin Oncol; 2020 Sep; 38(25):2902-2915. PubMed ID: 32639845
[TBL] [Abstract][Full Text] [Related]
29. Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group 'Survey' 1982-1992.
Cotterill SJ; Pearson AD; Pritchard J; Foot AB; Roald B; Kohler JA; Imeson J
Eur J Cancer; 2000 May; 36(7):901-8. PubMed ID: 10785596
[TBL] [Abstract][Full Text] [Related]
30. Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission.
Mora J; Castañeda A; Gorostegui M; Santa-María V; Garraus M; Muñoz JP; Varo A; Perez-Jaume S; Mañe S
Pediatr Blood Cancer; 2021 Oct; 68(10):e29121. PubMed ID: 34022112
[TBL] [Abstract][Full Text] [Related]
31. Poverty and Targeted Immunotherapy: Survival in Children's Oncology Group Clinical Trials for High-Risk Neuroblastoma.
Bona K; Li Y; Winestone LE; Getz KD; Huang YS; Fisher BT; Desai AV; Richardson T; Hall M; Naranjo A; Henderson TO; Aplenc R; Bagatell R
J Natl Cancer Inst; 2021 Mar; 113(3):282-291. PubMed ID: 33227816
[TBL] [Abstract][Full Text] [Related]
32. Long-term analysis of children with metastatic neuroblastoma treated in the ENSG5 randomised clinical trial.
Moreno L; Vaidya SJ; Schrey D; Pinkerton CR; Lewis IJ; Kearns PR; Machin D; Pearson ADJ;
Pediatr Blood Cancer; 2019 Apr; 66(4):e27565. PubMed ID: 30516328
[TBL] [Abstract][Full Text] [Related]
33. Survival and prognostic factors for childhood malignant liver tumors: analysis of harmonized clinical data.
Karalexi MA; Servitzoglou M; Moschovi M; Moiseenko R; Bouka P; Ntzani E; Kachanov D; Petridou ET; ;
Cancer Epidemiol; 2021 Feb; 70():101850. PubMed ID: 33220637
[TBL] [Abstract][Full Text] [Related]
34. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
Yalçin B; Kremer LC; van Dalen EC
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD006301. PubMed ID: 26436598
[TBL] [Abstract][Full Text] [Related]
35. Prognostic impact of gene expression-based classification for neuroblastoma.
Oberthuer A; Hero B; Berthold F; Juraeva D; Faldum A; Kahlert Y; Asgharzadeh S; Seeger R; Scaruffi P; Tonini GP; Janoueix-Lerosey I; Delattre O; Schleiermacher G; Vandesompele J; Vermeulen J; Speleman F; Noguera R; Piqueras M; Bénard J; Valent A; Avigad S; Yaniv I; Weber A; Christiansen H; Grundy RG; Schardt K; Schwab M; Eils R; Warnat P; Kaderali L; Simon T; Decarolis B; Theissen J; Westermann F; Brors B; Fischer M
J Clin Oncol; 2010 Jul; 28(21):3506-15. PubMed ID: 20567016
[TBL] [Abstract][Full Text] [Related]
36. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial.
Pearson AD; Pinkerton CR; Lewis IJ; Imeson J; Ellershaw C; Machin D; ;
Lancet Oncol; 2008 Mar; 9(3):247-56. PubMed ID: 18308250
[TBL] [Abstract][Full Text] [Related]
37. Anti-GD2 Based Immunotherapy Prevents Late Events in High-Risk Neuroblastoma Patients over 18 Months at Diagnosis.
Tas ML; Dootjes LW; Fiocco M; de Krijger RR; Dierselhuis MP; van Eijkelenburg NKA; van Grotel M; Kraal KCJM; Peek AML; Tytgat GAM; van Noesel MM
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638426
[TBL] [Abstract][Full Text] [Related]
38. Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era.
Kushner BH; Modak S; Kramer K; LaQuaglia MP; Yataghene K; Basu EM; Roberts SS; Cheung NK
Cancer; 2014 Jul; 120(13):2050-9. PubMed ID: 24691684
[TBL] [Abstract][Full Text] [Related]
39. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
Yalçin B; Kremer LC; Caron HN; van Dalen EC
Cochrane Database Syst Rev; 2013 Aug; (8):CD006301. PubMed ID: 23970444
[TBL] [Abstract][Full Text] [Related]
40. Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers.
Oberthuer A; Juraeva D; Hero B; Volland R; Sterz C; Schmidt R; Faldum A; Kahlert Y; Engesser A; Asgharzadeh S; Seeger R; Ohira M; Nakagawara A; Scaruffi P; Tonini GP; Janoueix-Lerosey I; Delattre O; Schleiermacher G; Vandesompele J; Speleman F; Noguera R; Piqueras M; Bénard J; Valent A; Avigad S; Yaniv I; Grundy RG; Ortmann M; Shao C; Schwab M; Eils R; Simon T; Theissen J; Berthold F; Westermann F; Brors B; Fischer M
Clin Cancer Res; 2015 Apr; 21(8):1904-15. PubMed ID: 25231397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
